A not-for-profit community journal that reviews the most important advances in the clinical management of HIV and access to treatment.
EASL 2014: summary of interferon free HCV studies with new DAAs
Rapid report on the most promising new drugs to treat hepatitis C...
Volume 15 Number 3/4 March/April 2014
CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments...
No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up
PARTNER starts to properly quantify this risk for anal sex and for gay men: headline news and rightly so...
ARV pipeline: doravirine, GSK-744 and BMS-068
Updates on these ARVs for the future...
Paediatric pipeline: CROI 2014 update on new antiretrovirals for children
Updates on rilpivirine, dolutegravir, elvitegravir, cobicistat and Stribild (Quad)
HTB supplement: 2013 pipeline report
HIV, hepatItIs C vIrus (HCV), and tuberculosIs (TB) drugs, diagnostics, vaccInes, and prevention technologIes in development
Editor: Simon Collins. Contributing editor: Polly Clayden. ISSN 1472-4863.
Subscriptions are free — by post, email and online.
Each issue of HTB is circulated for comments to our medical review board.
- EASL 2014: summary of interferon free HCV studies with new DAAs 15 April 2014.
- WHO publish treatment guidelines for hepatitis C 9 April 2014.
- Volume 15 Number 3/4 March/April 2014 24 March 2014.
- 21st Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 March 2014, Boston 24 March 2014.
- No HIV transmissions with undetectable viral load: interim PARTNER study results show need for longer follow-up 24 March 2014.
- PrEP injections every three months may protect against exposure from anal sex 24 March 2014.
- ARV pipeline: doravirine, GSK-744 and BMS-068 24 March 2014.
- Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study 24 March 2014.
- Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r 24 March 2014.
- Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257 24 March 2014.
- Pharmacokinetic targets for efavirenz might be too high 24 March 2014.
- Abacavir link to cardiovascular events in high-risk patients maintained in D:A:D study 24 March 2014.
- NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs 24 March 2014.
- HIV related infections remain the leading cause of maternal deaths in South Africa despite the availability of ART 24 March 2014.
- Lower newborn bone mineral content with maternal tenofovir use 24 March 2014.
- Paediatric pipeline: CROI 2014 update on new antiretrovirals for children 24 March 2014.
- Efavirenz maintenance therapy effective in children exposed to nevirapine prophylaxis 24 March 2014.
- Xpert TB test has important advantages but does not reduce morbidity 24 March 2014.
- Reports of a second baby possibly cured of HIV: uncertainty remains 24 March 2014.
- Updates on SB728-T, a CCR5-targeting gene therapy 24 March 2014.